Desmopressin
Desmopressin, sold under the trade name DDAVP among others, is a medication used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels. In hemophilia A and von Willebrand disease, it should only be used for mild to moderate cases. It may be given in the nose, by injection into a vein, by mouth, or under the tongue.
Clinical data | |
---|---|
Trade names | DDAVP (deamino D-arginine vasopressin), Minirin, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | IV, IM, SC, intranasal, by mouth, under the tongue |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Variable; 0.08–0.16% (by mouth) |
Protein binding | 50% |
Elimination half-life | 1.5–2.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.009 |
Chemical and physical data | |
Formula | C46H64N14O12S2 |
Molar mass | 1069.22 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(what is this?) (verify) |
Common side effects include headaches, diarrhea, and low blood sodium. The low blood sodium that results may cause seizures. It should not be used in people with significant kidney problems or low blood sodium. It appears to be safe to use during pregnancy. It is a synthetic analogue of vasopressin, the hormone that plays roles in the control of the body's osmotic balance, blood pressure regulation, kidney function, and reduction of urine production.
Desmopressin was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.